beloranib

Beloranib is a synthetic small molecule and an analog of fumagillin, developed as an inhibitor of methionine aminopeptidase 2 (METAP2). Initially designed as an angiogenesis inhibitor for cancer therapy, its clinical development shifted to focus on obesity and related metabolic disorders after METAP2 inhibition was found to induce significant weight loss. Beloranib acts by irreversibly inhibiting METAP2, which disrupts protein processing and downregulates pathways involved in fat storage and synthesis. This results in reduced hunger, increased utilization of stored fat for energy, and improvements in cardiometabolic risk factors. Clinical trials demonstrated substantial weight loss in obese patients—including those with Prader-Willi syndrome—but development was terminated following patient deaths during late-stage studies[1][2][4][5][6][8].

Other names

beloranib